207 related articles for article (PubMed ID: 25316294)
1. A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors.
Modlin IM; Aslanian H; Bodei L; Drozdov I; Kidd M
Endocr Connect; 2014 Dec; 3(4):215-23. PubMed ID: 25316294
[TBL] [Abstract][Full Text] [Related]
2. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
4. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
[TBL] [Abstract][Full Text] [Related]
5. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A as a Biochemical Marker for Neuroendocrine Tumors: A Single Center Experience at Royal Hospital, Oman.
Al-Risi ES; Al-Essry FS; Mula-Abed WS
Oman Med J; 2017 Sep; 32(5):365-370. PubMed ID: 29026467
[TBL] [Abstract][Full Text] [Related]
7. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
Raines D; Chester M; Diebold AE; Mamikunian P; Anthony CT; Mamikunian G; Woltering EA
Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
[TBL] [Abstract][Full Text] [Related]
8. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.
Modlin IM; Drozdov I; Kidd M
PLoS One; 2013; 8(5):e63364. PubMed ID: 23691035
[TBL] [Abstract][Full Text] [Related]
9. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.
Modlin IM; Kidd M; Falconi M; Filosso PL; Frilling A; Malczewska A; Toumpanakis C; Valk G; Pacak K; Bodei L; Öberg KE
Ann Oncol; 2021 Nov; 32(11):1425-1433. PubMed ID: 34390828
[TBL] [Abstract][Full Text] [Related]
10. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Waldum HL
Tumour Biol; 2010 Oct; 31(5):373-80. PubMed ID: 20480408
[TBL] [Abstract][Full Text] [Related]
11. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
[TBL] [Abstract][Full Text] [Related]
12. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease.
Kidd M; Modlin IM; Mane SM; Camp RL; Shapiro MD
Ann Surg; 2006 Feb; 243(2):273-80. PubMed ID: 16432362
[TBL] [Abstract][Full Text] [Related]
13. Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors.
Baekdal J; Krogh J; Klose M; Holmager P; Langer SW; Oturai P; Kjaer A; Federspiel B; Hilsted L; Rehfeld JF; Knigge U; Andreassen M
Diagnostics (Basel); 2020 Oct; 10(11):. PubMed ID: 33138020
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours.
Korse CM; Muller M; Taal BG
Br J Cancer; 2011 Oct; 105(8):1173-5. PubMed ID: 21989216
[TBL] [Abstract][Full Text] [Related]
15. Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.
Bodei L; Kidd M; Modlin IM; Prasad V; Severi S; Ambrosini V; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G; Drozdov I
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1341-52. PubMed ID: 25947577
[TBL] [Abstract][Full Text] [Related]
16. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
17. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC;
Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060
[TBL] [Abstract][Full Text] [Related]
19. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
[TBL] [Abstract][Full Text] [Related]
20. Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study.
van Treijen MJC; Korse CM; van Leeuwaarde RS; Saveur LJ; Vriens MR; Verbeek WHM; Tesselaar MET; Valk GD
Front Endocrinol (Lausanne); 2018; 9():740. PubMed ID: 30564197
[No Abstract] [Full Text] [Related]
[Next] [New Search]
